Formycon AG (LON:0W4N)
22.35
+0.15 (0.66%)
At close: Sep 12, 2025
Formycon AG Revenue
Formycon AG had revenue of 9.00M EUR in the half year ending June 30, 2025, a decrease of -79.45%. This brings the company's revenue in the last twelve months to 51.78M, down -14.84% year-over-year. In the year 2024, Formycon AG had annual revenue of 69.67M, down -10.32%.
Revenue (ttm)
51.78M EUR
Revenue Growth
-14.84%
P/S Ratio
7.42
Revenue / Employee
207.11K EUR
Employees
250
Market Cap
329.23M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 69.67M | -8.02M | -10.32% |
Dec 31, 2023 | 77.70M | 35.20M | 82.83% |
Dec 31, 2022 | 42.50M | 5.88M | 16.07% |
Dec 31, 2021 | 36.61M | 2.32M | 6.76% |
Dec 31, 2020 | 34.30M | 1.14M | 3.43% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |